Abstract: ObjectivesThe goal of the study was to assess the effects of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the composite of cardiovascular (CV) death, myocardial infarction (MI), and stroke, and on all-cause death, new-onset heart failure (HF), and new-onset diabetes mellitus (DM) in high-risk patients without HF.BackgroundACE-Is reduce CV events in high-risk patients without HF whereas the effects of ARBs are less certain.MethodsTwenty-six randomized trials comparing ARBs or ACE-Is versus placebo...
(read more)
Topics: 
Pharmacology
Internal medicine
Cardiology